Stem cell hope for Parkinson's: expanded access trial offers treatment to 11 patients
NCT ID NCT06056427
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This expanded access program provides multiple intravenous infusions of a patient's own stem cells (HB-adMSCs) to up to 11 people with Parkinson's disease who were eligible for but not randomized into a related Phase 2 trial. The goal is to evaluate safety and effectiveness in controlling disease symptoms. Participants must have already passed screening for the main study.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PARKINSON DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Planning ahead: could a simple program transform Parkinson's care?
- Sound waves vs. Parkinson's: can ultrasound calm tremors and stiffness?
- Can a nudge in your chart unlock Life-Saving genetic clues?
- Can MRI reveal the Brain's response to deep brain stimulation?
- Can we outsmart Gaucher's hidden toll on lungs, bones, and brain?
- Could a brain disease change behavior years before diagnosis?